Alzecure Pharma Ab · OMXSTO:ALZCUR
Alzecure Pharma Ab — Aktiespararna presentation June 13, 2023
30 slides from Alzecure Pharma Ab's conference presentation, Jun 13, 2023
Slide 1: AlzeCure Pharma - Projects in Alzheimer's & Pain
Aktiespararna June 13, 2023 ALZECURE PHARMA - Projects in Alzheimer’s & Pain Martin Jönsson, CEO
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements regarding the Company’s intentions, assessments, or expectations in respect of the Company’s future results, financial position, liquidity, development, prospects, expected growth, strategies and possibilities as well as the market wit
Slide 3: Agenda
Agenda • Who we are • Focus areas • Pipeline & the science • Progress, achievements & goals
Slide 4: AlzeCure Pharma – in brief
AlzeCure Pharma – in brief Ø Working in Alzheimer’s Disease (AD) and Pain – Hugh unmet medical need & multi-billion sales potential Ø Spin-out from AstraZeneca – as a result of them ending their CNS projects Ø Founded in 2016, out of a research foundation sponsored by Alzheimerfonden Ø Experienced t
Slide 5: Our Business Model
Our Business Model • We are a Research & Development company • Research & develop through early clinical phase and then to out-license or partner on our projects • Gain incomes through: − Upfront payments − Milestone payments − Royalties on sold products 5
Slide 6: Small molecule drugs – AlzeCure's approach for increased success
Small molecule drugs – AlzeCure’s approach for increased success DIFFERENCES BETWEEN SMALL MOLECULES & BIOLOGICS* SMALL MOLECULE LARGE BIOLOGIC DRUG Additional benefits: - Oral medications - Low production costs - … AlzeCure focus Monoclonal antibody Small molecule drug c. 25,000 atoms Smaller molec
Slide 7: A pipeline of small-molecule programs
A pipeline of small-molecule programs – Multiple candidates increase chance of success Platform Candidate Indication Research phase Preclinical phase Phase I Phase II Phase III NeuroRestore® Alzheimer’s Disease, Positive read-out Phase I trial Sleep disorders, ACD856 Traumatic brain injuries Safety,
Slide 8: Close cooperation with leading experts & institutions
Close cooperation with leading experts & institutions Professor Bengt Winblad Professor Maria Eriksdotter Professor Henrik Zetterberg Karolinska Institute Karolinska Institute Sahlgrenska and UCL
Slide 9: Alzheimer's Disease
Our primary Focus area Alzheimer’s Disease • EVERY FIVE SECOND a new person is diagnosed with Alzheimer’s • Costs the society more than oncology & cardiovascular diseases TOGETHER • The patient population & costs are expected to TRIPLE in the next 30 years 9
Slide 10: Tripling patient population – due to the aging population
Tripling patient population – due to the aging population 150m 75m 50m 2020 2030 2050 • 50 million people worldwide live with dementia … • … and doubling every 20 years • Alzheimer’s accounts for 60 - 80% of all dementia cases 10
Slide 11: Progress & Increased Activity in the Alzheimer's field
Progress & Increased Activity in the Alzheimer’s field De-risking • Validation of treatment approach: - Amyloid protein targeting • Positive out-comes in clinical trials, - incl in phase III + approvals • Vastly improved biomarkers & diagnostics identifying patients => increased probability of succe
Slide 12: Two Alzheimer's platforms - 1st-in-class potentials & future game-changers
Two Alzheimer’s platforms - 1st-in-class potentials & future game-changers MEETING NEEDS OF AD PATIENTS – ADRESSING SHORT TERM NEEDS WITH LONG-TERM BENEFITS Preventive Disease-modifying therapy Symptomatic & pot. Disease-modifying therapy Alzstatin® NeuroRestore® MoA: Gamma-secretase modulator MoA:
Slide 13: Alzstatin
Preventing or delaying Alzheimer’s Alzstatin® MoA: Gamma-Secretes-Modulator Targeting Toxic Amyloid Production - Novel Oral Small Molecule
Slide 14: Stop Alzheimer's develop
AlzeCure’s GSM* Alzstatin® reducing Ab-42^ to diminishing the build-up of toxic fragments and plaque => STOP ALZHEIMER’S DEVELOP 14 *) GSM = Gamma Secretes Modulator. ^) AB-42 = Amyloid beta 42
Slide 15: Alzstatin – Gamma-Secretase Modulator
Alzstatin® – Gamma-Secretase Modulator Alzheimer’s Disease Modifier – Preventing or delay disease progression ALZHEIMER'S DISEASE PROGRESSION A-beta-42 - main culprit in Alzheimer’s progression Pre-symptomatic Alzheimer Symptomatic Alzheimer 10-20 years 7-10 years Aggregation effect Amyloid plaques
Slide 16: Target patient population - Alzstatin vs Antibodies
Alzstatin® – Gamma-Secretase Modulator Brain status at intended treatment initiation Target patient population - Alzstatin ® vs Antibodies Alzstatin® Anti-bodies Healthy brain at risk Mild Alzheimer’s of Alzheimer’s • The antibody Aduhelm has the indication, “Mild Alzheimer’s disease”*, where the br
Slide 17: How Alzstatin is expected to differ from the Antibodies
Alzstatin® – Gamma-Secretase Modulator How Alzstatin is expected to differ from the Antibodies* - Key advantages Small molecule therapy Oral formulation => Home treatment • Small molecules generally pass much more readily • Don’t need to go to the hospital once or twice a across the BBB to its targe
Slide 18: Multiple target populations: Preventive & Maintenance Therapy
Alzstatin® – Gamma-Secretase Modulator Multiple target populations: - Preventive & Maintenance Therapy • Preventive therapy - based on genetic risk factors* and biomarkers • Early stand-alone treatment before onset of symptoms and any major neurodegeneration occurring • Prevents build-up of amyloid
Slide 19: NeuroRestore
Improving Learning & Memory Capabilities NeuroRestore® Trk-PAM Improving Neuronal Function & Cognition - Novel Oral Small Molecule
Slide 20: NeuroRestore – Positive Allosteric Modulator of Trk-receptors
NeuroRestore® – Positive Allosteric Modulator of Trk-receptors NeuroRestore – to Improve Learning & Memory Capabilities BDNF/ NGF The compounds, e.g. ACD856, acts as enhancers of neurotrophin, e.g. + Trk-receptor BDNF and NGF signalling Cell membrane • AlzeCure’s compounds act as enhancers of neurot
Slide 21: NeuroRestore - Cognitive Enhancer Improving Learning & Memory Capability
NeuroRestore® – Positive Allosteric Modulator of Trk-receptors NeuroRestore - Cognitive Enhancer Improving Learning & Memory Capability Stages of memory formation LEARN STORE REMEMBER Transforming Maintaining the Re-accessing the information into a form encoded information from that can be stored in
Slide 22: NeuroRestore ACD856: potential for disease modification
NeuroRestore® – Positive Allosteric Modulator of Trk-receptors NEW DATA Potential also for Disease Modification => Improving Brain Health NeuroRestore ACD856: ü Increases the levels of BDNF in cortical neurons ü Improves mitochondrial function and acts neuroprotective in an energy-deprived neurotoxi
Slide 23: NeuroRestore ACD856 – Candidate in clinical trials
Press release NeuroRestore ACD856 – Candidate in clinical trials - Patent in the US to 2039 https://www.alzecurepharma.se/en/alzecure-receives-us-patent-for-neurorestore-acd856/
Slide 24: Our platform PAINLESS – Targeting unmet medical needs within pain
Our platform PAINLESS – Targeting unmet medical needs within pain Osteoarthritis & severe Neuropathic pain* pain conditions > 300 million patients 600 million pa9ents Project: TrkA-NAM Project: ACD440 24 *) Neuropathic pain = Pain initiated or caused by a primary lesion or dysfunction in the somatos
Slide 25: ACD440 – Novel TRPV1 antagonist in phase 2 for neuropathic pain
ACD440 – TRPV1 antagonist ACD440 – Novel TRPV1 antagonist in phase 2 for neuropathic pain PROJECT OVERVIEW › Approximately SEK 200m already invested on project development Emanates from › Mode of action confirmed in several Phase 1 clinical trials Big Pharma › Synthesized compound and formulation de
Slide 26: Positive phase 2a read-out in peripheral neuropathic pain
ACD440 – TRPV1 antagonist NEW DATA* POSTITIV phase 2a read-out in peripheral neuropathic pain • ACD440 demonstrated positive proof-of-mechanism (PoM) results in patients with chronic peripheral neuropathic pain, i.e. the drug candidate has an effect on the intended target mechanism • A significant pai
Slide 27: Neuropathic pain - Fast growing market
Neuropathic pain - Fast growing market • The most valuable segment within the pain indications • Poorly served patients • Huge demand for better drugs 2020 CAGR to 2027 $11 billions 12.9% => $25 billions The Neuropathic Pain market was valued at $10,8 billion in 2020 globally and is forecast to reac
Slide 28: Key milestones & activities in 2023
Key milestones & activities in 2023 m Progress Alzstatin® ACD680 into the next phase, pre-clinical development Prepare pre-IND meeting on NeuroRestore® ACD856 with FDA for next clinical study Advance Painless TrkA-NAM into pre-clinical safety testing towards a clinical candidate Out-license or partn
Slide 29: Key investment highlights in AlzeCure
Key investment highlights in AlzeCure Targeting areas of huge unmet medical needs m Strong team with extensive experience and track record – from idea to clinic Platforms with first-in-class properties and potential game-changers Parallel investments in several candidates and potent follow-up progra
Slide 30: Karolinska Institutet Novum Science Park
Karolinska Institutet Novum Science Park Hälsovägen 7, 141 57 Stockholm SWEDEN www.alzecurepharma.com
AlzeCure Pharma — Aktiespararna presentation June 13, 2023 on 6ix